Juno Therapeutics (NASDAQ:JUNO): The mean short term price target for Juno Therapeutics (NASDAQ:JUNO) has been established at $61.13 per share. The higher price target estimate is at $80 and the lower price target estimate is expected at $50 according to 8 Analyst. The stock price is expected to vary based on the estimate which is suggested by the standard deviation value of $11.52
Many analysts have stated their opinion on the company shares. Raymond James initiates coverage on Juno Therapeutics (NASDAQ:JUNO). The shares have now been rated Outperform by the stock experts at the ratings house. The rating by the firm was issued on June 2, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (General Counsel & Secretary) of Juno Therapeutics, Inc., Cassidy Bernard J had sold 3,116 shares worth of $122,241 in a transaction dated May 19, 2016. In this transaction, 3,116 shares were sold at $39.23 per share.
Juno Therapeutics (NASDAQ:JUNO) stock ended Monday session in the red zone in a volatile trading. The stock closed down 1.71 points or 3.98% at $41.27 with 1,851,549 shares getting traded. Post opening the session at $42.51, the shares hit an intraday low of $40.61 and an intraday high of $43.32 and the price was in this range throughout the day. The company has a market cap of $4,355 million and the number of outstanding shares have been calculated to be 105,535,597 shares. The 52-week high of Juno Therapeutics (NASDAQ:JUNO) is $60.5 and the 52-week low is $22.37.
Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.